ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 29, 2024.

Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit 
Fireside Chat: Monday, April 29, 2024 at 10:30 a.m. EDT
Panel: Gene Therapy: Positioning for CMC Success at Every Stage at 4:00 p.m. EDT
Location: Virtual

A live webcast of the panel can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.

ABOUT REGENXBIO Inc.

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for retinal and rare diseases, including ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, RGX-202 for the treatment of Duchenne and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' ZOLGENSMA for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit www.regenxbio.com.

Contacts:

Dana Cormack
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Investors:
Chris Brinzey, ICR Westwicke
339-970-2843
This email address is being protected from spambots. You need JavaScript enabled to view it.